Immunic (NASDAQ:IMUX) Stock, Quote.Headers.trade-ideas

Immunic

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

YelpLogoAugust2021

News

Initiation

Markets

Analyst Ratings

Trading Ideas

BHVN

COYA

IMUX

YELP

This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday

Long Ideas

Penny Stocks

Small Cap

Insider Trades

Pre-Market Outlook

FRTX

The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Immunic And 2 Other Stocks Under $2 Insiders Are Buying

Movers

Immunic, Inc. (NASDAQ: IMUX) shares are roughly flat following strength early Friday after the company announced a three-tranche private placement of up to $240 million.

What&#39;s Going On With Immunic Stock?

Immunic Inc

Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) has outperformed the market over the past 10 years by 19.27% on an annualized basis producing an average annual return of 31.14%. Currently, Fabrinet has a market capitalization of $8.71 billion. 
Buying $1000 In FN: If an investor had bought $1000 of FN stock 10 years ago, it would be worth $15,243.02 today based on a price of $240.23 for FN at the time of writing.
<h3>Fabrinet's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733958910_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Fabrinet 10 Years Ago Would Be Worth Today

Pharmacy-benefit managers (PBMs) have been scrutinized for their role in drug distribution for years. Now a bipartisan group of lawmakers is threatening to break up the companies behind these <a href="https://www.benzinga.com/general/health-care/24/11/42097386/cvs-healthcignaunitedhealths-pharmacy-benefit-managers-accuse-ftc-of-overreach-in-effort-to-reshape-drug-rebate-system">so-called drug middlemen</a>.
What To Know: According to a Wall Street Journal <a href="https://www.wsj.com/politics/policy/warren-hawley-health-insurers-pbm-bill-c8cdeb85?mod=latest_headlines">report</a>, Sen. Elizabeth Warren (D.-Mass.) and Sen. Josh Hawley (R.-Mo.) have sponsored a Senate bill that would require the companies that own health insurance units or PBMs to divest those businesses over the next three years.
A companion bill was also reportedly introduced in the House on Wednesday. 
The legislation could cut off a significant source of revenue for these companies and bring an end to ongoing frustration for patients.
"PBMs have manipulated the market to enrich themselves — hiking up drug costs, cheating employers, and driving small pharmacies out of business," Warren said.
Hawley added that the legislation will stop health care companies from charging &#8220;more and more for less.&#8221;
CVS Health Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) Caremark, Cigna Group&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) Express Scripts and UnitedHealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) OptumRx are the three largest PBMs. Shares of these companies turned lower Wednesday when news of the bills surfaced.
"Any policies that would limit our ability to negotiate with drugmakers and pharmacies would ultimately increase the cost of medicine in the United States, and in many cases, serve as a handout to the pharmaceutical industry," a&nbsp;CVS Health&nbsp;spokesperson reportedly said.
See Also: <a href="https://www.benzinga.com/news/earnings/24/12/42449013/adobe-q4-earnings-revenue-eps-beat-on-strong-demand-related-to-ai-shares-slide-following-soft-guidance">Adobe Q4 Earnings: Revenue, EPS Beat On Strong Demand Related To AI, Shares Slide Following Soft Guidance</a>
The report indicates the bills are not likely to gain traction in Congress until next year, but supporters are attempting to lay the groundwork for potential passage in 2025.
The role of PBMs in the healthcare industry has been <a href="https://www.benzinga.com/24/12/42365853/unitedhealthcare-faces-tough-questions-following-insurance-business-ceos-tragic-death">challenged by several dissatisfied patients</a> across social platforms following the murder&nbsp;of&nbsp;UnitedHealthcare&nbsp;CEO&nbsp;Brian Thompson. Luigi Mangione <a href="https://www.benzinga.com/news/legal/24/12/42423214/luigi-mangione-fights-extradition-to-new-york-on-murder-charge-shouts-at-press-outside-courthouse">has been charged</a> with killing Thompson. 
CVS, CI, UNH Price Action: CVS shares closed Wednesday down 6.15% at $51.76, Cigna Group closed the session down 5.57% at $294.03 and UnitedHealth closed down 5.60% at $533.53, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Government

Health Care

Politics

Bipartisan Lawmakers Aim To Break Up Health Care Giants With New Legislation

Macy's Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) revealed the findings of its investigation into a significant accounting mishap that impacted its financial reporting <a href="https://www.benzinga.com/quote/M/news">over several years.</a>
The inquiry determined that a single employee's repeated errors and subsequent coverup led to $151 million in falsely recorded expenses, The Wall Street Journal <a href="https://www.wsj.com/business/retail/macys-m-q3-earnings-report-2024-c7363662">reports</a>.
What Happened: The discrepancies, which stemmed from understated small package delivery expenses starting in late 2021, were perpetuated by intentional erroneous entries and falsified documentation. This manipulation concealed the true costs until its discovery in the fall of 2024. 
While Macy's terminated the employee responsible, the company stated the individual did not gain financially from the misconduct, WSJ reports.
Also Read: <a href="https://www.benzinga.com/24/12/42447332/alphabets-quantum-willow-chip-wows-analyst-google-at-the-leading-edge-of-technology-innovation">Alphabet&#8217;s Quantum Willow Chip Wows Analyst: Google At The &#8216;Leading Edge Of Technology Innovation&#8217;</a>
Why It Matters: The timing of the investigation and its fallout couldn't be more critical, given the holiday shopping season's importance to retail. With net sales declining by 2.4% to $4.7 billion for the recent quarter, the company is striving to rebuild investor trust and refocus on operational improvements.
On Wednesday, the company announced adjusted earnings per share for the third quarter that still managed to beat expectations despite the scandal, coming in at $0.04 versus a consensus of $0.03. Macy's highlighted sales strength at its first 50 locations, Bloomingdale's and Bluemercury, partially <a href="https://www.benzinga.com/news/earnings/24/12/42436387/macys-lowers-annual-profit-forecast-amid-accounting-misstep-stock-tumbles">offsetting broader declines. </a>
According to The Journal, CEO&nbsp;Tony Spring&nbsp;emphasized the need to "strengthen existing controls" to prevent future errors of this magnitude.
Macy's also announced plans to close 65 stores this year, surpassing its initial estimate of 55, and raised $66 million through asset sales during the quarter. Despite these measures, activist investors continue to pressure the retailer to unlock more value, including considering a real estate spinoff.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/12/42447567/magnificent-seven-tech-titans-hit-182-trillion-market-cap-alphabet-amazon-apple-meta-tesla-jointly-notch-all-time-highs">Magnificent Seven Tech Titans Hit $18.2 Trillion Market Cap: Alphabet, Amazon, Apple, Meta, Tesla Jointly Notch All-Time Highs</a></li>
</ul>
Photo: Shutterstock

Macy's Employee Hid $151 Million In Costs Over Several Years

Earnings

17 Education & Technology Q3 Adjusted Earnings Per ADS $(0.16) Up From $(0.85) YoY, Sales $8.50M Up From $6.18M YoY

President-elect Donald Trump is expected to be named the TIME Person of the Year, according to a new report. The official announcement will happen Thursday morning and could coincide with his first time ringing the opening bell at the<a href="https://www.benzinga.com/politics/24/12/42445514/trump-to-open-nyse-thursday-as-markets-surge"> New York Stock Exchange.</a>
What Happened: TIME recently released a short list of finalists for the 2024 TIME Person of the Year, which included both Trump and his <a href="https://www.benzinga.com/general/social-media/24/11/41784933/donald-trumps-wealth-soars-with-2024-election-win-heres-how-much-president-elect-is-worth-ho">2024 presidential election opponent</a> Vice President Kamala Harris.
Trump has emerged as the winner, as <a href="https://www.politico.com/news/2024/12/11/time-trump-person-of-the-year-000498">reported </a>by Politico. The award would mark the second for Trump, who also won the award back in 2016. Trump would become the first president to win the award since Joe Biden, who shared it with Harris in 2020.
Trump's win would also mark the first two-time win by a president since Barack Obama, who won the award in 2008 and 2012. A total of 14 U.S. presidents have won the award, which was first handed out in 1927.
Musician Taylor Swift <a href="https://www.benzinga.com/general/entertainment/23/12/36118811/did-sam-altman-get-robbed-taylor-swift-wins-time-person-of-the-year-over-openai-founder">won the award last year </a>beating out a short list of finalists that included OpenAI CEO Sam Altman. TIME CEO Jessica Sibley rang the NYSE opening bell last year to mark the cover reveal. The timing of Trump's ringing of the bell and the award being officially announced by TIME on Thursday have now been linked by Politico.
The <a href="https://time.com/7200122/person-of-the-year-2024-shortlist/">short list </a>for this year's Person of the Year award included Trump, Harris, Kate Middleton, Elon Musk and Benjamin Netanyahu. Prior to narrowing the field to five finalists, Jerome Powell, Yulia Navalnaya, Joe Rogan, Claudia Sheinbaum and Mark Zuckerberg were also under consideration.
TIME has also been handing out additional awards in recent years. Caitlin Clark was named the Athlete of the Year by the media outlet. Elton John was named this year's Icon of the Year and Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) Lisa Su was named CEO of the Year.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent121124">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
 Why It's Important: The TIME Person of the Year has named politicians, world leaders, celebrities and CEOs winners of the annual award. The award is not always given to a good person, but instead to the person who had the biggest affect on the things that happened in the past year.
Past wins by Adolf Hitler and Joseph Stalin have often been used to show the lack of importance of the award.
Trump has been critical of the award in the past and upset that he did not receive it on several occasions.
In 2013, Trump said the annual award was "a joke and stunt of a magazine that, like Newsweek, soon be dead."
Later in 2015 when he was a finalist on the list, Trump was critical for not making the cover over then-German Chancellor Angela Merkel.
"It means a lot, especially me growing up reading Time magazine. And you know, it's a very important magazine," Trump said at the time.
Coincidentally, the Trump prosecutors were among the finalists for last year's award, along with Altman, Swift, Vladimir Putin, Barbie, the Hollywood strikers, Xi Jinping, Powell and King Charles III.
Trump was the betting favorite on prediction sites like <a href="https://kalshi.com/markets/kxtime/times-person-of-the-year">Kalshi </a>and <a href="https://polymarket.com/event/time-2024-person-of-the-year?tid=1733870773380">Polymarket </a>with odds of around 80% prior to the Wednesday report that he was the winner of the award. Trump's odds stand at 99% on Kalshi and 98% on Polymarket at the time of writing.
Some may be upset that Musk, the CEO of Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), didn't win this year's award with the surge in Tesla's stock price and his soaring wealth thanks to other ventures like xAI and SpaceX.
Musk <a href="https://www.benzinga.com/markets/cryptocurrency/21/12/24568117/elon-musk-named-times-2021-person-of-the-year">won the award </a>in 2021. The billionaire and his supporters will likely be pleased that the presidential candidate he endorsed in the 2024 election won the award, if it had to go to someone else.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/management/24/12/42444955/elon-musk-first-person-worth-400-billion-as-tesla-stock-hits-new-all-time-highs-how-2024-election-helped-could-lead-to-future-gains">Elon Musk First Person Worth $400 Billion As Tesla Stock Hits New All-Time Highs: How 2024 Election Helped, Could Lead To Future Gains</a></li>
</ul>
Photo: Shutterstock

Media

TSLA

Donald Trump To Be Named TIME Person Of The Year, Beating Out Harris, Musk, Middleton, Netanyahu: Report

United Rentals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>) has outperformed the market over the past 20 years by 12.39% on an annualized basis producing an average annual return of 20.86%. Currently, United Rentals has a market capitalization of $52.30 billion. 
Buying $1000 In URI: If an investor had bought $1000 of URI stock 20 years ago, it would be worth $44,031.49 today based on a price of $796.97 for URI at the time of writing.
<h3>United Rentals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733957108_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) has outperformed the market over the past 15 years by 10.67% on an annualized basis producing an average annual return of 22.72%. Currently, Mastercard has a market capitalization of $490.53 billion. 
Buying $1000 In MA: If an investor had bought $1000 of MA stock 15 years ago, it would be worth $21,690.34 today based on a price of $534.45 for MA at the time of writing.
<h3>Mastercard's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733956218_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

The U.S. airline industry is gearing up for a blockbuster year in 2025, Morgan Stanley analysts say, predicting airline companies on the brink of what could be a &#8220;perfect storm of tailwinds that essentially propels the <a href="https://www.benzinga.com/topic/airlines">industry to make money.&#8221;</a>
Equity analyst Ravi Shanker reiterated a bullish stance on the airlines industry in a Wednesday note. 
The U.S. Global Jets ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JETS#NYSE">JETS</a>) has rallied 36% year-to-date, outperforming by about 9 percentage points the broader stock market as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>). 
<h3 class="wp-block-heading">Premium Carriers Poised For Another Stellar Year </h3>
&#8220;We expect demand to remain resilient with volume growth,&#8221; Shanker said. Legacy carriers like United Airlines Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) and Delta Air Lines Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) are reaping the rewards of what analysts call "the premiumization trend,&#8221; he added.
According to Morgan Stanley, these carriers benefit not just from ticket sales but from steady ancillary revenue streams, including loyalty programs, credit cards, and brand partnerships.
In 2024, UAL's stock soared over 150%, leading Morgan Stanley to raise its price target from $88 to $130. However, the extraordinary run places a high bar for further gains. 
Alaska Air Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) climbed to Morgan Stanley's top pick for 2025, with an upgraded price target of $90 on the back of "upsized synergy targets at their recent Investor Day."
<h3 class="wp-block-heading">Domestic Airlines Eye A Comeback</h3>
While premium carriers dominated in 2024, several domestic-focused airlines are staging a resurgence. Low-cost and ultra-low-cost carriers, including JetBlue Airways Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) and Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>), faced a tough year marked by operational challenges and restructuring efforts.
"The other big shift in 2024 was several domestic carriers fundamentally changing their business models to fly less, fly differently, bundle fares, and move upmarket," Morgan Stanley highlighted. 
As these carriers stabilize operations, easier year-over-year comparisons position them for a strong recovery. 
Morgan Stanley resumed coverage of JBLU at &#8216;Equalweight&#8217; with a 12-month price target of $8. 
&#8220;We like the elements of the JetForward plan but note that the turnaround is likely to be slower with more elements outside of management&#8217;s control than other Domestic peers,&#8221; Shanker wrote.
<h3 class="wp-block-heading">Industry Metrics Flash Green For 2025</h3>
Morgan Stanley expects 2025 to mark the first sustained period where revenue per available seat mile (RASM) exceeds cost per available seat mile (CASM). 
This dynamic is expected to boost margins across the board, a stark reversal from earlier pandemic years. 
Analysts project mid-single-digit (MSD) volume growth for the industry, supported by constrained capacity growth at low-single-digit (LSD) levels​.
Fueling optimism is a favorable jet fuel environment. Prices are forecast to hover in the low $2 per gallon range through 2026, providing airlines with critical cost stability. "
This is the sweet spot of the industry where pricing can drop through to the bottom line while offering an added incentive for capacity to remain rational," Morgan Stanley wrote in the note​.
<h3 class="wp-block-heading">Investor Sentiment: Opportunities And Risks</h3>
Despite 2024's strong performance, airline valuations remain compelling. Analysts note that stocks like ALK, AAL, and DAL trade below historical earnings multiples, offering attractive upside potential. 
Yet, risks loom, including macroeconomic headwinds and the possibility of a slowdown in consumer spending in the second half of 2025.
Morgan Stanley also flagged the return of institutional investors as a positive catalyst. "The potential return of large, sticky capital bases for the first time in 10 years could set another leg or three in the stocks' run in 2025," Shanker said​.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42444498/bank-of-america-raises-bullish-outlook-on-us-brokers-exchanges-alternative-investments-3-top-picks-for-2025">Bank Of America Raises Bullish Outlook On US Brokers, Exchanges, Alternative Investments: 3 Top Picks For 2025</a></li>
</ul>
Image: Best Airports 2024 &#x7C; Image generated using Dall-E

Analyst Color

Large Cap

Mid Cap

Sector ETFs

Broad U.S. Equity ETFs

Price Target

Reiteration

Travel

Econ #s

ETFs

JBLU

JETS

US Airlines Set To Fly High In 2025, Analyst Says: 'Perfect Storm Of Tailwinds' Will Propel Industry Gains

Management

Valley National Bancorp Says Thomas Iadanza Has Notified His Intention To Retire From His Position As President Effective June 30, 2025

Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) has outperformed the market over the past 20 years by 4.43% on an annualized basis producing an average annual return of 12.9%. Currently, Ross Stores has a market capitalization of $51.31 billion. 
Buying $100 In ROST: If an investor had bought $100 of ROST stock 20 years ago, it would be worth $1,120.06 today based on a price of $153.83 for ROST at the time of writing.
<h3>Ross Stores's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733955307_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ROST

$100 Invested In Ross Stores 20 Years Ago Would Be Worth This Much Today

On December 9, 2024, Telomir entered into a Stock Purchase Agreement with a certain accredited investor, pursuant to which the Company issued 142,857 shares of common stock at a price of $7 per share for a total of $1 million, a 20% premium to the closing price of the Company's common stock on the date of the transaction.&nbsp;
The transaction did not involve the issuance of any warrants. This transaction follows a $5 million non-dilutive line of credit extended to the Company earlier this year by the same accredited investor, which remains undrawn to date.

Offerings

TELO

Telomir Pharmaceuticals Raises $1M At $7 Per Share In No-warrant, Restricted Common Stock Deal - Filing

Chewy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) shares are moving lower in Wednesday&#8217;s after-hours session after the company announced a public offering by a selling stockholder and a <a href="https://www.benzinga.com/pressreleases/24/12/b42448132/chewy-inc-announces-public-offering-of-class-a-common-stock-by-selling-stockholder-and-concurrent-">concurrent share repurchase</a>.
What Happened: After the market close on Wednesday, Chewy announced an underwritten public offering of&nbsp;$500 million&nbsp;of its common stock, being sold by Buddy Chester Sub LLC, an entity affiliated with funds advised by Chewy&#8217;s largest shareholder&nbsp;BC Partners Advisors.
The selling stockholder plans to grant the underwriters a 30-day option to purchase up to an additional $75 million of Chewy common stock. Chewy will not be selling any shares in the offering, and will not receive any proceeds. 
In connection with the offering, Chewy agreed to purchase $50 million of its common stock at the same price paid by the underwriters in the offering. The repurchased shares will be retired upon completion. The concurrent repurchase was approved by a special committee of Chewy&#8217;s board.
Check This Out: <a href="https://www.benzinga.com/news/large-cap/24/12/42447567/magnificent-seven-tech-titans-hit-182-trillion-market-cap-alphabet-amazon-apple-meta-tesla-jointly-notch-all-time-highs">Magnificent Seven Tech Titans Hit $18.2 Trillion Market Cap: Alphabet, Amazon, Apple, Meta, Tesla Jointly Notch All-Time Highs</a>
Chewy shares are up approximately 37% year-to-date. The rally in the pet retailer&#8217;s stock accelerated over the summer after meme stock trader&nbsp;Keith Gill,&nbsp;also known as&nbsp;&#8220;Roaring Kitty,&#8221;&nbsp;announced a stake in the company. 
Gill <a href="https://www.benzinga.com/news/24/10/41614177/roaring-kitty-puts-chewy-stock-in-the-litter-box-gamestop-shares-move-higher-after-hours">sold his entire stake</a> in Chewy a few months later. Chewy shares fell on the news, but the selloff was short-lived. Chewy had been Gill's only other publicly known investment outside of GameStop Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>), which has seen increased attention in recent months.
GameStop and several other meme stocks popped last week after Gill <a href="https://www.benzinga.com/general/social-media/24/12/42349100/gamestop-rockets-as-roaring-kitty-returns-to-x-what-does-his-tweet-signal-ahead-of-q3-earnings">posted an image</a> of a TIME magazine cover featuring a blank computer screen and a video player paused at the 1:09 mark of a 4:20-long video. Chewy shares traded lower on the post.
Chewy reported mixed quarterly financials last week, beating on earnings but missing on revenue. The company guided for fourth-quarter revenue of $3.18 billion to $3.2 billion versus estimates of $3.17 billion.
Following the print, Goldman Sachs lifted its <a href="https://www.benzinga.com/analyst-stock-ratings">price target</a> to $40, RBC Capital raised its target to $42 and JPMorgan maintained an Overweight rating and moved its price target up to $38.
CHWY Price Action: Chewy shares were down 2.92% in after-hours, trading at $31.59 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Courtesy of Chewy.

After-Hours Center

CHWY

Chewy Stock Slides As Investors Digest $500M Offering From Largest Shareholder

Net revenues were RMB59.6 million ($8.5 million), compared with net revenues of RMB45.1 million in the third quarter of 2023.
 &nbsp;

17 Education & Technology Q3 Sales $8.5M, Up From Prior Year

The award of this project, expected to generate approximately $100 million in revenue, is from a new customer based in New South Wales, a region that is also new to MacKellar, reflecting our objective of geographic and customer diversification. The project is set to begin in the first quarter of 2025 and completion is scheduled for the second quarter of 2026.&nbsp;

Contracts

NACG Subsidiary MacKellar Secures An Early Works And Development Contract From A Major Copper Producer In The Australian State Of New South Wales

Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) has outperformed the market over the past 15 years by 1.93% on an annualized basis producing an average annual return of 13.99%. Currently, Analog Devices has a market capitalization of $107.47 billion. 
Buying $1000 In ADI: If an investor had bought $1000 of ADI stock 15 years ago, it would be worth $7,074.62 today based on a price of $216.55 for ADI at the time of writing.
<h3>Analog Devices's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733954426_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Analog Devices Stock In The Last 15 Years

Arthur A. Weiss informed the Board that he will retire from the Board on December&nbsp;31, 2024, Stephanie W. Bergeron informed the Board that she will not stand for re-election to the Board at the Company's 2025 Annual Meeting of Shareholders, and Clunet R. Lewis informed the Board that he intends to retire from the Board no later than the Company's 2026 Annual Meeting of Shareholders.&nbsp;
The Company has retained a director search firm to assist in the identification of qualified candidates for the Board.

Sun Communities Reveals Several Upcoming Changes To Its Board As Part Of Its Ongoing Refreshment Strategy

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is the top stock pick in the automotive sector for 2025, Morgan Stanley analysts led by Adam Jonas said in a note covering electric vehicles (EVs).
Tesla Top Stock Pick: Jonas&#8217; note came ahead of Tesla hitting <a href="https://www.benzinga.com/analyst-ratings/price-target/24/12/42434317/tsla-stock-surges-in-premarket-after-multiple-price-target-hikes">new all-time highs </a>Wednesday.
Jonas reiterated an Overweight rating on Tesla and raised the price target from $310 to $400.
"Elon Musk's entry into the political sphere has expanded investor thinking around Tesla's fundamental outlook," Jonas said of Tesla CEO Elon Musk.
<a href="https://www.benzinga.com/news/management/24/12/42444955/elon-musk-first-person-worth-400-billion-as-tesla-stock-hits-new-all-time-highs-how-2024-election-helped-could-lead-to-future-gains">Tesla stock rallied</a> since the 2024 presidential election. The big question is whether the move is temporary or the start of more to come.
"Will Tesla begin to play a greater role in the US renewable/autonomous industrial complex?" Jonas asks.
Jonas said client conversation see enthusiasm for AI, data centers, renewable energy and robotics. The conversations acknowledge that it's important for the U.S. to be a leader in these sectors, Jonas added.
"Based on our discussions, at least, Tesla is very frequently excluded from the potential paths of expression in a portfolio."
Tesla's total addressable market outside of its core automotive market is likely to expand. It might not be included in financial models for the stock, Jonas said.
Jonas said there could be risks on Tesla's autonomous vehicles and more items over time. But the close relationship between Musk and President-elect Donald Trump could prove key to unlocking value. Government and industrial partnerships could prove key for growth in EVs, autonomous vehicles and robotics, Jonas added.
"Elon Musk's emergence from a political ‘outsider' to having a voice in potential policies may, at some level, accelerate Tesla's journey beyond autos."
You may not be a billionaire like Elon Musk, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/general/biotech/24/12/42366750/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">check out five stocks flying under the radar that deserve your attention.</a>
Other Auto Picks: Outside of Tesla, Jonas and team see a "bumpy road" ahead for EVs and autonomous vehicles.
"The US election result has extended the ‘ICE is Nice' trade for a bit longer but keep on the lookout for hidden value in the EV ecosystem into the 2H," Jonas said.
Jonas upgraded General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) from Underweight to Equal-Weight and raised the price target from $46 to $54.
The analyst said smaller EV companies could be the most at risk with the new administration. Trump promised <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">to end EV credits</a>.
"While Tesla may see share gain long term even with a less supportive EV regulatory backdrop, smaller scale EV start-ups Rivian and Lucid may see greater risks to production."
Jonas has an Equal-Weight rating on Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) and an Underweight rating on Lucid Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>).
Rivian's valuation has the appropriate risk/reward for the balance between trying to achieve profitability and trying to get value out of its technology, the analyst added.
Price Action: Tesla stock closed Wednesday 5.93% higher at $424.77, hitting new all-time highs of $424.88 during the trading session. Tesla stock is up 71% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41501607/tesla-q3-earnings-highlights-eps-beat-revenue-miss-shares-climb-on-2025-timeline-for-lower-cost-evs">Tesla Q3 Earnings Highlights: EPS Beat, Revenue Miss, Shares Climb On 2025 Timeline For Lower-Cost EVs</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Upgrades

LCID

RIVN

Tesla Is Analyst's Top 2025 Stock Pick: Elon Musk Political Involvement May 'Accelerate' EV Maker Beyond Autos

With <a href="https://www.benzinga.com/quote/AVGO/earnings">fourth quarter results</a> set to be unveiled on Dec. 12, Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) is projected to deliver a standout performance. Rosenblatt analyst Hans Mosesmann expects a "beat and modest raise" for the quarter, driven by the company's surging AI-related silicon revenue and VMware upside.
Broadcom's AI networking revenue is forecast to hit $3.5 billion this quarter, growing 10% sequentially. &#8220;We see revenues being driven by AI-related silicon strength,&#8221; says Mosesmann.
The anticipated fourth quarter revenue of $14.0 billion would reflect a 51% year-over-year increase, solidifying Broadcom's position as an AI powerhouse.
Read Also: <a href="https://www.benzinga.com/news/contracts/24/12/42418681/broadcom-enhances-open-source-ecosystem-with-bitnami-premium-release">Broadcom Enhances Open-Source Ecosystem with Bitnami Premium Release</a>
<h2 class="wp-block-heading">2025 Outlook: AI Leads, But Non-AI Plays Recover</h2>
Looking ahead, Mosesmann foresees Broadcom guiding above consensus for the January quarter. With AI-related revenue expected to exceed $12 billion in 2024, the momentum doesn't stop there. 
He predicts, &#8220;Non-AI semiconductor revenue should continue its recovery in CY25, while Infrastructure Software is likely to be driven by VMware strength.&#8221;
<h2 class="wp-block-heading">ASICs Vs. GPUs: A Win For Both</h2>
The competitive landscape between Broadcom's custom ASICs and Nvidia Corp&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) GPUs often sparks debate, but Mosesmann calls it &#8220;an apples-to-oranges comparison.&#8220; He adds, &#8220;We see AI ASICs outgrowing GPU compute over the next several years,&#8221; highlighting Broadcom's growth potential in AI acceleration, Gen AI and networking across Cloud and Edge.
<h2 class="wp-block-heading">A Strong Setup For 2025</h2>
Mosesmann reiterates his Buy rating on Broadcom with a $240 price target, backed by &#8220;a low-30s P/E multiple on our FY26 Non-GAAP EPS.&#8221; 
As Broadcom CEO Hock Tan emphasizes that AI compute will thrive on &#8220;open&#8221; industry connectivity standards, the company looks well-positioned for long-term success.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/12/42439155/broadcom-stock-jumps-on-apple-ai-chip-report-whats-going-on">Broadcom Stock Jumps On Apple AI Chip Report: What&#8217;s Going On?</a></li>
</ul>
Photo: Shutterstock

Previews

Tech

AVGO

NVDA

Broadcom's AI Edge: 'Apples-to-Oranges Comparison' Shows ASICs Outgrowing GPUs, Says Analyst

Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) has outperformed the market over the past 5 years by 7.82% on an annualized basis producing an average annual return of 21.53%. Currently, Carvana has a market capitalization of $32.25 billion. 
Buying $1000 In CVNA: If an investor had bought $1000 of CVNA stock 5 years ago, it would be worth $2,629.95 today based on a price of $250.95 for CVNA at the time of writing.
<h3>Carvana's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733953508_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVNA

$1000 Invested In Carvana 5 Years Ago Would Be Worth This Much Today

Aquilino served as the 26th commander of the U.S. Indo-Pacific Command, responsible for all U.S. military activities in the Indo-Pacific, from 2021 until his retirement as a four-star admiral in July 2024.

Lockheed Martin Adds John C. Aquilino To Board

Immunic Q3 2024 Earnings Preview

Immunic GAAP EPS of -$0.24 misses by $0.02

"During the third quarter, we have continued to advance both our phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS) and o...

Immunic reports Q3 EPS (24c), consensus (22c)

Immunic, Inc. 2024 Q3 - Results - Earnings Call Presentation

Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript

Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Immunic (IMUX – Research Report) on November 7 and set a price target of $5.00....

Optimistic Buy Rating for Immunic Driven by Promising Trials and Market Opportunities for VidoCa

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Adaptimmune Therapeutics (ADAP – Research Report),...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)

H.C. Wainwright analyst Matthew Caufield initiated coverage of Immunic (IMUX) with a Buy rating and $10 price target The firm likes the company's "...

Immunic initiated with a Buy at H.C. Wainwright

Analyst William Wood of B.Riley Financial reiterated a Buy rating on Immunic (IMUX – Research Report), retaining the price target of $6.00. William...

Immunic's Promising Pipeline Progress and Stable Financials Justify Buy Rating

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Actinium Pharmaceuticals (ATNM – Research Report), N...

Comments

Immunic

Immunic (IMUX) Forecast

Immunic (NASDAQ:IMUX) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga